<!DOCTYPE html>
<!--[if lt IE 7]>      <html class="no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]-->
<!--[if IE 7]>         <html class="no-js lt-ie9 lt-ie8"> <![endif]-->
<!--[if IE 8]>         <html class="no-js lt-ie9"> <![endif]-->
<!--[if IE ]> <html class="no-js IE"> <![endif]-->
<!--[if IE ]> <html class="no-js IE"> <![endif]-->
<!--[if gt IE 8]><!--> <html class="no-js"> <!--<![endif]-->
    <head>
        <meta charset="utf-8">
        <meta http-equiv="X-UA-Compatible" content="IE=edge">
        <title></title>
        <meta name="description" content="">
        <meta name="viewport" content="width=device-width, initial-scale=1">
        <link rel="stylesheet" href="css/styles.css">
        <link rel="stylesheet" href="css/customStyles.css">
    </head>
    <body class="team">
        <div id="header">
            <div class="header agilvaxLogoSmallScreen center">
                <a href="index.html"><img src="images/agilvaxHeaderLogo.png" alt="Agilvax" title="Agilvax" width="135"></a>
            </div>

            <div class="navigation">
                    <div class="mobileNavToggle">Menu</div>
                    <div class="navigationBar">
                        <ul class="nav navLeft">
                        </ul><!-- /nav -->
                        <ul class="nav navRight">
                        </ul><!-- /nav -->
                    </div><!-- /navigationBar -->
            </div><!-- /navigation -->
        </div><!-- #header -->

        <div class="pageTitle">
            <div class="containerNarrow">
                <h1 class="slideInBT">Agilvax Team</h1>
            </div>
        </div><!-- /pageTitle -->

        <div class="mainContent">
            <div class="container">
                <h2>Team</h2>
                <div class="breakColMobile">
                    <div class="oneFourth">
                        <a class="card AgilvaxSolution theTeam" id="federicaTrigger">
                            <h3 class="teamMemberName">Federica Pericle, <i>PhD, MBA</i></h3>
                            <p class="teamMemberTitle">President and CEO</p>
                        </a>
                    </div><!-- /oneFourth -->
                    <div class="oneFourth">
                        <a class="card AgilvaxSolution theTeam" id="michaelTrigger">
                            <h3 class="teamMemberName">Michael Perrine, <i>MS, MBA</i></h3>
                            <p class="teamMemberTitle">Director of Business Development</p>
                        </a>
                    </div><!-- /oneFourth -->
                    <div class="oneFourth">
                        <a class="card AgilvaxSolution theTeam" id="mitchellTrigger">
                            <h3 class="teamMemberName">Mitchell Tyler, <i>PhD</i></h3>
                            <p class="teamMemberTitle">Director of Research and Development</p>
                        </a>
                    </div><!-- /oneFourth -->
                    <div class="oneFourth gridLast">
                        <a class="card AgilvaxSolution theTeam" id="deeTrigger">
                            <h3 class="teamMemberName">Dee Brescia,</h3>
                            <p class="teamMemberTitle">Chief Financial Officer</p>
                        </a>
                    </div><!-- /oneFourth gridLast -->
                    <div class="oneFourth">
                        <a class="card AgilvaxSolution theTeam" id="constanceTrigger">
                            <h3 class="teamMemberName">Constance Dorian,</h3>
                            <p class="teamMemberTitle">Director of Technical Operations</p>
                        </a>
                    </div><!-- /oneFourth -->
                    <div class="oneFourth">
                        <a class="card AgilvaxSolution theTeam" id="oRourkeTrigger">
                            <h3 class="teamMemberName">John P O’Rourke Jr.<i>PhD</i></h3>
                            <p class="teamMemberTitle">Director of Platform Technology</p>
                        </a>
                    </div><!-- /oneFourth -->
                    <div class="oneFourth">
                        <a class="card AgilvaxSolution theTeam" id="gabrielaTrigger">
                            <h3 class="teamMemberName">Gabriela Aguilar,</h3>
                            <p class="teamMemberTitle">IR Coordinator/Executive Administrator</p>
                        </a>
                    </div><!-- /oneFourth -->
                </div><!-- /breakColMobile -->
                
                <div class="clear"></div>
                <h2>Board of Directors</h2>
                <div class="breakColMobile">
                    <div class="oneFourth">
                        <a class="card AgilvaxSolution" id="wanetaTrigger">
                            <h3 class="teamMemberName">Waneta Tuttle, <i>PhD, MBA</i></h3>
                        </a>
                    </div><!-- /oneFourth -->
                    <div class="oneFourth">
                        <a class="card AgilvaxSolution" id="betoTrigger">
                            <h3 class="teamMemberName">Ebetuel (Beto) Pallares, <i>PhD</i></h3>
                        </a>
                    </div><!-- /oneFourth -->
                    <div class="oneFourth">
                        <a class="card AgilvaxSolution" id="stuartTrigger">
                            <h3 class="teamMemberName">Stuart Rose, <i>PhD</i></h3>
                        </a>
                    </div><!-- /oneFourth -->
                    <div class="oneFourth gridLast">
                        <a class="card AgilvaxSolution" id="brianTrigger">
                            <h3 class="teamMemberName">Brian Birk <i>&nbsp;</i></h3>
                        </a>
                    </div><!-- /oneFourth gridLast -->
                </div><!-- /breakColMobile -->

                <div class="clear"></div>
                <h2>Advisory Board</h2>
                <div class="breakColMobile">
                    <div class="oneFourth">
                        <a class="card AgilvaxSolution" id="davidTrigger">
                            <h3 class="teamMemberName">David Peabody, <i>PhD</i></h3>
                        </a>
                    </div><!-- /oneFourth -->
                    <div class="oneFourth">
                        <a class="card AgilvaxSolution" id="bryceTrigger">
                            <h3 class="teamMemberName">Bryce Chackerian, <i>PhD</i></h3>
                        </a>
                    </div><!-- /oneFourth -->
                    <div class="oneFourth">
                        <a class="card AgilvaxSolution" id="frankTrigger">
                            <h3 class="teamMemberName">Frank Borriello, <i>MD, PhD</i></h3>
                        </a>
                    </div><!-- /oneFourth -->
                    <div class="oneFourth gridLast">
                        <a class="card AgilvaxSolution" id="dougTrigger">
                            <h3 class="teamMemberName">Doug Watts, <i>MS, PhD</i></h3>
                        </a>
                    </div><!-- /oneFourth gridLast -->
                </div><!-- /breakColMobile -->
            </div><!-- /containerNarrow -->
        </div><!-- /MainContent -->
       

        <!-- TeamOverlays -->
        <div id="federicaOverlay" class="overlay">
            <div class="olContent">
                <h2 class="teamMemberName">Federica Pericle, <i>PhD, MBA</i></h2>
                <p class="teamMemberTitle">President and Chief Executive Officer</p>
                <hr>
                <div class="scrollableContent">
                    <p>Dr. Pericle is an accomplished entrepreneur and senior manager in the biotech industry with over 20 years of experience in scientific, strategic and leadership positions. She has a track record of management experience in research & clinical development and business units in biotech companies and comprehensive life science analyst experience within financial institutions.</p>
                    <p>Dr Pericle  is also the founder of several biotechnology companies including SeneXta Therapeutics, SA and EP Pharma, Inc., dedicated to the treatment of CNS and oncology.</p>
                    <p>Previously, Dr. Pericle has worked as scientific advisor for Agennix, Inc. a biopharmaceutical company focused on developing protein-based drugs for oncology and as Director of the Oncology Program at Valentis, in Houston, Texas. She has also worked as Senior Scientist at the National Cancer Institute.</p>
                    <p>Dr. Pericle has 20 years of research experience in the fields of immunology, cancer gene therapy, tumor biology, signal transduction and cancer immunotherapy.</p>
                    <p>She has led the development of 10 product candidates for the treatment of cancer/CNS and has published over 40 scientific articles in peer-review journals.</p>
                    <p>Dr. Pericle is well acquainted with FDA regulations, clinical trial design and the overall strategy on how to move a product from research into clinical development.</p>
                    <p>She received her Ph.D. in Biological Sciences from Turin University in Italy with a specialization in Immunology/Cancer Immunotherapy from the University of South Florida. She also holds an MBA from Texas A&M University.</p>
                </div><!-- /scrollableContent -->
                <div class="closeOL">X</div>
            </div><!-- /olContent -->
        </div><!-- /#federicaOverlay -->
        <div id="constanceOverlay" class="overlay">
            <div class="olContent">
                <h2 class="teamMemberName">Constance Dorian,</h2>
                <p class="teamMemberTitle">Director of Technical Operations</p>
                <hr>
                <div class="scrollableContent">
                    <p>Constance Dorian brings more than 20 years of experience in the Diagnostic/Pharmaceutical Biotechnical field.</p>
                    <p>She gained her experience working at start-up to medium sized biotech companies in the San Diego Area.</p>
                    <p>Constance began her career as a bench chemist and worked her way up in the industry to become an expert in Manufacturing Operations following GMP/FDA Guidelines.</p>
                    <p>She has a broad and deep knowledge of the design, development and transfer process of R&D products to scale up and validation of those products for the manufacturing process.</p>
                    <p>She is a specialist in nearly all aspects of manufacturing operations. Constance earned her B. S. in Biology from San Diego State University.</p>
                </div><!-- /scrollableContent -->
                <div class="closeOL">X</div>
            </div><!-- /olContent -->
        </div><!-- /#constanceOverlay -->
        <div id="michaelOverlay" class="overlay">
            <div class="olContent">
                <h2 class="teamMemberName">Michael Perrine, <i>MS, MBA</i></h2>
                <p class="teamMemberTitle">Director of Business Development</p>
                <hr>
                <div class="scrollableContent">
                    <p>Michael Perrine has most recently overseen the development and transition of Azano Biotech into an organization focused on providing the scientific community with essential research use tools to promote biomedical discoveries and breakthroughs.</p>
                    <p>Mr. Perrine is excited to bring his talents to Agilvax to aid in the commercialization efforts of the unique VLP technology platform.</p>
                    <p>Mr. Perrine has attained an extensive technical and business understanding of the biotechnology industry through his research and development work at Azano Biotech, Exagen Diagnostics, nanoMR, and Physiogenix.</p>
                    <p>Mr. Perrine was part of research teams that developed a novel breast cancer prognostic assay, a noninvasive assay for the diagnosis of gastrointestinal diseases, a rapid assay for the detection of sepsis, and performed preclinical pharmaceutical screening of early stage hypertension and diabetes therapeutics.</p>
                    <p>Mr. Perrine holds an MBA from the University of New Mexico's Anderson School of Management and an MS in Physiology from the Medical College of Wisconsin.</p>
                </div><!-- /scrollableContent -->
                <div class="closeOL">X</div>
            </div><!-- /olContent -->
        </div><!-- /#michaelOverlay -->
        <div id="mitchellOverlay" class="overlay">
            <div class="olContent">
                <h2 class="teamMemberName">Mitchell Tyler, <i>PhD</i></h2>
                <p class="teamMemberTitle">Director of Research and Development</p>
                <hr>
                <div class="scrollableContent">
                    <p>Dr. Mitchell Tyler recently graduated with a PhD in Biomedical Sciences from the University of New Mexico where he studied under the inventors of the Agilvax technology.</p>
                    <p>His dissertation focused on the development of a next-generation human papillomavirus vaccine utilizing bacteriophage virus-like particles displaying peptides derived from HPV proteins.</p>
                    <p>While a graduate student, Dr. Tyler was awarded a competitive T-32 NIH training grant from the Center of Infectious Disease and Immunity at UNM and published several papers in peer-reviewed journals.</p>

                </div><!-- /scrollableContent -->
                <div class="closeOL">X</div>
            </div><!-- /olContent -->
        </div><!-- /#mitchellOverlay -->
        <div id="deeOverlay" class="overlay">
            <div class="olContent">
                <h2 class="teamMemberName">Dee Brescia,</h2>
                <p class="teamMemberTitle">Chief Financial Officer</p>
                <hr>
                <div class="scrollableContent">
                    <p>Dee Brescia has served as Agilvax’s Chief Financial Officer since 2013. Prior to joining Agilvax, Ms. Brescia served as Vice President of Operations and Chief Financial Officer for PhDx Systems, a company that develops proprietary clinical study software, for 12 years.</p>
                    <p>Ms. Brescia has also held the title of Director of Accounting at the Lovelace Respiratory Research Institute, and Accountant for Southwest Medical Ventures.</p>
                    <p>Ms. Brescia has a BS in accounting from the University of Wisconsin Eau Claire, an MBA in accounting from the University of New Mexico’s Anderson School of Management, and is a Certified Public Accountant in New Mexico and Colorado.</p>
                </div><!-- /scrollableContent -->
                <div class="closeOL">X</div>
            </div><!-- /olContent -->
        </div><!-- /#deeOverlay -->

        <!-- board of directors -->
        <div id="wanetaOverlay" class="overlay">
            <div class="olContent">
                <h2 class="teamMemberName">Waneta Tuttle, <i>PhD, MBA</i></h2>
                <hr>
                <div class="scrollableContent">
                    <p>Waneta C. Tuttle, Ph.D., M.B.A. is the owner and CEO of Southwest Medical Ventures (SMV), a life sciences and health care venture development company. Through SMV, she was the founding CEO of Indigo Medical, (acquired by Johnson & Johnson’s Ethicon Endosurgery), PhDx Systems, Inc. and Exagen Diagnostics, Inc.</p>
                    <p>SMV is the managing member of Puente Partners, LLC and Southwest Medical Technologies, LLC (SMT). The Puente Partners portfolio includes nanoMR, Inc. and Azano Pharma, Inc. SMT was organized in 2010 to create new ventures focused on technology spin-offs and roll-ups. SMT's first company is AgilVax, Inc.</p>
                    <p>Until its sale to Eisai Pharmaceuticals, Inc. in January of 2008, Dr. Tuttle served as a Director of NASDAQ listed MGI Pharma, Inc., an oncology and acute care focused biopharmaceutical company. She is a Director of Health Care Service Corporation, a mutual legal reserve company operating Blue Cross/Blue Shield of Illinois, New Mexico, Oklahoma and Texas and is a Member of the Corporation at the Charles Stark Draper Laboratories in Boston. She serves as Southwest Regional Advisor to Tullis Health Investors and to the Tullis-Dickerson funds.</p>
                    <p>Prior to founding SMV in 1992, Dr. Tuttle held positions of increasing responsibility over 23 years at the Lovelace Medical Foundation in Albuquerque. She began her career at the Foundation as a research scientist, and then served for many years as its Vice President and Chief Operating Officer. She was also a member of the management committee for the integrated health care delivery system at Lovelace and served on the Boards of Directors for several of the Lovelace organizations.</p>
                    <p>Dr. Tuttle’s Ph.D. is in biology with a concentration in physiology. She also holds an M.B.A. from the R.O. Anderson Schools of Management at the University of New Mexico and has been inducted into the Anderson Schools Hall of Fame.</p>
                </div><!-- /scrollableContent -->
                <div class="closeOL">X</div>
            </div><!-- /olContent -->
        </div><!-- /#wanetaOverlay -->
        <div id="betoOverlay" class="overlay">
            <div class="olContent">
                <h2 class="teamMemberName">Ebetuel (Beto) Pallares, <i>PhD</i></h2>
                <hr>
                <div class="scrollableContent">
                    <p>Dr. Ebetuel Pallares founded Joseph Advisory Services (JAS) in 2006. He brings extensive domestic and international start-up experience as an entrepreneur and in conducting due diligence for both start-ups and late stage companies. His professional experience spans working for top-tier strategy consulting firms, co-founding start-ups, international business development, nonprofit management, venture capital and military service.</p>
                    <p>In the summer of 2009, he co-founded Cottonwood Capital Partners, the general partner of Cottonwood Technology Fund, a seed and early-stage venture fund with headquarters in El Paso, TX. He serves on several corporate and nonprofit boards.</p>
                    <p>He is also an advisor to the UT Horizon Fund, the venture capital investment fund of the University of Texas System, he is the Investor in Residence for NMSU's Arrowhead Center, and serves on the limited partnership advisory committees of several venture funds.</p>
                    <p>He graduated from Brandeis University, in Waltham, MA, with a degree in economics, and received his MBA from The University of Texas at El Paso (UTEP). He also went on to attain a Ph.D. in International Business from UTEP.</p>
                    <p>Dr. Pallares' research has focused on confluence of high tech emerging market firms, incubators and technology commercialization. Dr. Pallares is married, and enjoys fatherhood. When not watching his kids while his wife, a professional photographer, is on assignment, he engages in reading, writing and community service, including service in Rotary International and Gideons International.</p>
                </div><!-- /scrollableContent -->
                <div class="closeOL">X</div>
            </div><!-- /olContent -->
        </div><!-- /#betoOverlay -->
        <div id="stuartOverlay" class="overlay">
            <div class="olContent">
                <h2 class="teamMemberName">Stuart Rose, <i>PhD</i></h2>
                <hr>
                <div class="scrollableContent">
                    <p>Dr. Stuart Rose is the founder of The BioScience Center in Albuquerque, where AgilVax is located. He has over 40 years of experience in the pharmaceutical industry.</p>
                    <p>Prior to establishing the Center in 2012, he served as President and CEO of Oso Biopharmaceutical Manufacturing, a CMO for injectables. Prior to OsoBio he was President and CEO of Penick Corporation, VP/Worldwide Manufacturing for ICN Pharmaceuticals (now Valeant) and VP/General Manager of ICN Europe. He also served as Senior Vice President at Par Pharmaceuticals. He spent the majority of his early career with American Cyanamid's pharmaceutical arm, Lederle Laboratories, where he rose to VP of International Manufacturing and Logistics.</p>
                    <p>Dr. Rose holds a Ph.D. in Chemistry from Wayne State University in Detroit, Michigan.</p>
                </div><!-- /scrollableContent -->
                <div class="closeOL">X</div>
            </div><!-- /olContent -->
        </div><!-- /#stuartOverlay -->
        <div id="brianOverlay" class="overlay">
            <div class="olContent">
                <h2 class="teamMemberName">Brian Birk</h2>
                <hr>
                <div class="scrollableContent">
                    <p>Brian Birk is Managing Partner and 2006 co-founder of Sun Mountain Capital and has over 20 years experience as an operating executive and investor.</p>
                    <p>Prior to forming Sun Mountain Capital, Birk was Vice President and Director of Private Equity at Fort Washington Capital Partners where he helped the firm establish and manage a number of private equity direct investment funds, secondary investment funds, and fund of funds programs.</p>
                    <p>Birk has held a senior manager position at the Boston Consulting Group and finance manager positions at General Electric and GE Capital. Birk has an MBA from the Kellogg School of Management and a BS in economics from Carleton College.</p>
                </div><!-- /scrollableContent -->
                <div class="closeOL">X</div>
            </div><!-- /olContent -->
        </div><!-- /#brianOverlay -->

        <!-- advisory board -->
        <div id="davidOverlay" class="overlay">
            <div class="olContent">
                <h2 class="teamMemberName">David Peabody, <i>PhD</i></h2>
                <hr>
                <div class="scrollableContent">
                    <p>Dr. David Peabody is a Professor in the University of New Mexico’s Department of Molecular Genetics and Microbiology and a co-inventor of the Agilvax technology.</p>
                    <p>He was trained at Stanford University in the laboratory of Paul Berg (Nobel Prize, 1980) and has been associated with the University of New Mexico since 1984.</p>
                    <p>For a number of years he studied RNA viruses of bacteria as model systems to understand gene regulation, but in recent years has focused on adapting the virus-like particles of these bacteriophages as platforms for vaccine development and targeted drug delivery.</p>
                </div><!-- /scrollableContent -->
                <div class="closeOL">X</div>
            </div><!-- /olContent -->
        </div><!-- /#davidOverlay -->
        <div id="bryceOverlay" class="overlay">
            <div class="olContent">
                <h2 class="teamMemberName">Bryce Chackerian, <i>PhD</i></h2>
                <hr>
                <div class="scrollableContent">
                    <p>Dr. Bryce Chackerian is an Associate Professor in the University of New Mexico’s Department of Molecular Genetics and Microbiology and co-inventor of the Agilvax Technology.</p>
                    <p>As a post-doctoral fellow in Dr. John Schiller’s laboratory at the National Cancer Institute he began his work on using Virus-like particles (VLPs) as platform for antigen display.</p>
                    <p>Since moving to the University of New Mexico in 2004 his laboratory has shown that VLP presentation can enhance the immunogenicity of numerous target epitopes, including epitopes derived from self-antigens, which are normally subject to the mechanisms of B cell tolerance.</p>
                    <p>His work has focused on the development of new vaccines against infectious agents, as well as self-antigens involved in chronic diseases.</p>
                </div><!-- /scrollableContent -->
                <div class="closeOL">X</div>
            </div><!-- /olContent -->
        </div><!-- /#bryceOverlay -->
        <div id="frankOverlay" class="overlay">
            <div class="olContent">
                <h2 class="teamMemberName">Frank Borriello, <i>MD, PhD</i></h2>
                <hr>
                <div class="scrollableContent">
                    <p>Dr. Frank Borriello is a biopharma executive with 15 years of industry experience. Trained as a clinical pathologist and immunologist, in 1999 Frank transitioned from an academic research faculty position at the Brigham and Women’s Hospital to the Wyeth Oncology Clinical Development Group.</p>
                    <p>At Wyeth, Frank was recruited as a line function expert for business development (BD) activities and has been actively engaged in technical analysis and BD ever since.</p>
                    <p>He has honed these skills both in the biopharm industry as well as in the financial and consulting sectors.</p>
                    <p>During a 5 year tenure at Millennium-Takeda Frank was primarily responsible for the two most significant oncology BD deals; a Seattle Genetics license and the Intellikine acquisition.</p>
                    <p>More recently Frank has been with Shire Corporate Due Diligence focused on the rare diseases business unit and has been part of the technical due diligence effort that culminated in the Viropharma acquisition.</p>
                    <p>Frank has significant BD and technical due diligence experience spanning the scientific, medical and financial facets of drug development with assets of all types (e.g. biologics, peptides, nucleic acids and small molecules) and all stages of development (e.g. preclinical to marketed).</p>
                </div><!-- /scrollableContent -->
                <div class="closeOL">X</div>
            </div><!-- /olContent -->
        </div><!-- /#frankOverlay -->
        <div id="dougOverlay" class="overlay">
            <div class="olContent">
                <h2 class="teamMemberName">Doug Watts, <i>MS, PhD</i></h2>
                <hr>
                <div class="scrollableContent">
                    <p>Dr. Watts has nearly 30 years experience conducting field and laboratory research on the ecology and epidemiology infectious diseases, with emphasis on zoonotic viral diseases, from his time with the Department of Defense (DoD).</p>
                    <p>Dr. Watts held several key scientific administrative positions that enabled him to acquire extensive experience in managing, advising, and directing research on enteric, parasitic and viral diseases in Asia, Africa, and South America.</p>
                    <p>During Dr. Watts tenure at the University of Texas Medical Branch (UTMB) at Galveston from 2002 to 2008, and in his current position as the Executive Director of Veterinary Services and Institutional Biosafety, and the Co-Director of the Border Biomedical Research Center at the University of Texas at El Paso (UTEP), Dr. Watts has focused on emerging viral disease and the evaluation of candidate therapeutics and vaccines for Severe Acute Respiratory Disease Syndrome and West Nile viruses.</p>
                    <p>Dr. Watts developed a candidate yellow fever vaccine and participated in a WRCE project that evaluated antiviral drugs for monkeypox.</p>
                    <p>Dr. Watts was also the lead investigator in studies that led to the development of a murine model for SARS and prairie dogs as a model for monkeypox disease.</p>
                    <p>Dr. Watts continues to conduct research on emerging viral diseases, including projects to evaluate therapeutic compounds for dengue, surveillance of mosquitoes for arboviruses in USA – Mexico border communities and the evaluation of the role the cellular immune response for affording protection against Rift Valley Fever.</p>
                </div><!-- /scrollableContent -->
                <div class="closeOL">X</div>
            </div><!-- /olContent -->
        </div><!-- /#doughOverlay -->
        <div id="oRourkeOverlay" class="overlay">
            <div class="olContent">
                <h2 class="teamMemberName">John P O’Rourke Jr., <i>PhD</i></h2>
                <p class="teamMemberTitle">Director of Platform Technology</p>
                <hr>
                <div class="scrollableContent">
                    <p>Dr. John P O’Rourke Jr. is the Director of Platform Technology at Agilvax, Inc.  In this role he is contributing to the advancement the company’s cancer immunotherapy and vaccine pipeline. Dr. O’Rourke obtained his Bachelor of Science degree in Chemistry from Northern Illinois University and his Ph.D. from the Ohio State University.  He received postdoctoral training at Nationwide’s Children’s Research Institute in Columbus, OH and the University of New Mexico.  Dr. O’Rourke is currently enrolled in the Executive MBA program at the University of New Mexico’s Anderson School of Management.  Prior to joining Agilvax, Dr. O’Rourke was an Assistant Research Professor at the University of New Mexico School of Medicine.   </p>
                    <p>Dr. O’Rourke has over 20 years’ experience in the development and application of molecular and cell biology techniques to fundamental problems in oncology.  He joined Agilvax from the University of New Mexico where his most recent research was in the development and application of virus-like-particle (VLP) affinity selection for the development of novel vaccines and adjuvant.  Dr. O’Rourke has published multiple articles on cancer biology and VLP vaccine development in high impact journals.</p>
                </div><!-- /scrollableContent -->
                <div class="closeOL">X</div>
            </div><!-- /olContent -->
        </div><!-- /#doughOverlay -->
        <div id="gabrielaOverlay" class="overlay">
            <div class="olContent">
                <h2 class="teamMemberName">Gabriela Aguilar</h2>
                <p class="teamMemberTitle">Investor Relations Coordinator/Executive Administrator</p>
                <hr>
                <div class="scrollableContent">
                    <p>Gabriela Aguilar is the Investor Relations Coordinator/Executive Administrator for Agilvax, Inc.</p>
                    <p>For the past fifteen years, Gabriela has been working in both the Academic and Industry sectors. She has gained experience in logistics, purchasing, management, marketing and overall Administration duties working for Expeditors International (Freight Forwarder), Cardinal Health, Inc, and the University of Texas at El Paso.</p>
                    <p>Gabriela graduated with a Bachelor’s Degree in Business Administration with a major in Marketing and a minor in Logistics from New Mexico State University.</p>
                </div><!-- /scrollableContent -->
                <div class="closeOL">X</div>
            </div><!-- /olContent -->
        </div><!-- /#doughOverlay -->


        <div id="footer">
        </div><!-- /footer -->

        <script src="http://ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js"></script>
        <script src="http://ajax.googleapis.com/ajax/libs/jqueryui/1.10.4/jquery-ui.min.js"></script>
        <script src="js/modernizr-2.6.2.min.js"></script>
        <script src="js/plugins.js"></script>

<script>
// Triggers
$('#federicaTrigger').click(function () {
    $('#federicaOverlay').addClass('active');
});
$('#constanceTrigger').click(function () {
    $('#constanceOverlay').addClass('active');
});
$('#michaelTrigger').click(function () {
    $('#michaelOverlay').addClass('active');
});
$('#mitchellTrigger').click(function () {
    $('#mitchellOverlay').addClass('active');
});
$('#deeTrigger').click(function () {
    $('#deeOverlay').addClass('active');
});
$('#wanetaTrigger').click(function () {
    $('#wanetaOverlay').addClass('active');
});
$('#betoTrigger').click(function () {
    $('#betoOverlay').addClass('active');
});
$('#stuartTrigger').click(function () {
    $('#stuartOverlay').addClass('active');
});
$('#brianTrigger').click(function () {
    $('#brianOverlay').addClass('active');
});
$('#davidTrigger').click(function () {
    $('#davidOverlay').addClass('active');
});
$('#bryceTrigger').click(function () {
    $('#bryceOverlay').addClass('active');
});
$('#frankTrigger').click(function () {
    $('#frankOverlay').addClass('active');
});
$('#dougTrigger').click(function () {
    $('#dougOverlay').addClass('active');
});
$('#oRourkeTrigger').click(function () {
    $('#oRourkeOverlay').addClass('active');
});
$('#gabrielaTrigger').click(function () {
    $('#gabrielaOverlay').addClass('active');
});

// close overlay
$('.closeOL').click(function () {
    $('.overlay.active').removeClass('active');
});
$('.overlay').click(function () {
    $(this).removeClass('active');
});
</script>

        <!-- LoadIncludes -->
        <script>
            $( ".navLeft" ).load( "includes/nav.html" );
            $( ".navRight" ).load( "includes/navRight.html" );
            $( "#footer" ).load( "includes/footer.html" );
        </script>
        <script src="js/main.js"></script>

    </body>
</html>
